We have read with interest the paper of Venditti et al (1) in the Journal. The authors show similar results than previously reported in terms of severity of disease and mortality in the health care related (HCR) group. (2,3,4) We miss the data on the etiology of pneumonia. The association between multiresistant pathogens and HCR- infections has been well established previously (2,3). The high mortality rate that the authors found in HCR pneumonia (HCRP) could be due in part to the greater risk of inappropriate therapy in this group. It is therefore surprising that mortality was not associated with HCR or hospital acquired (HA) categories in multivariate analysis.
Recently, we examined the clinical characteristics and outcomes of a homogenous group of patients with bacteremic pneumococcal pneumonia (BPP) and their relation with the health care system (HCRS) (unpublished data). From Jan 2004 to June 2007, all consecutive adult patients with BPP seen in our hospital were prospectively enrolled. Data obtained included demographics, co morbidities, Pitt score, presence of shock, relation with the HCS and in-hospital mortality. 140 episodes of BPP were identified. Community acquired pneumonia (CAP) was diagnosed in 106 (75%) patients, HCRP in 25 (18%) and HA pneumonia (HAP) in 9 patients (6.4%); mean age was 66.8 (SD 18), 57 (SD 20) and 75 years (SD 12), respectively (p<0.001). Patients with HCRP and HAP presented more commonly with coma and had an increased LOS. Fatality rates in HCRP were similar to HAP (32% vs. 33.3%)and higher than CAP mortality (9.3%, p=0.005). Patients with pneumococcal HCRP presented the highest early mortality (within 72 h of admission) (87.5% vs. 50% in CAP, p<0.001). Few patients received inappropriate therapy and, interestingly enough, it was equally represented among groups.
Multiresistance and inappropriate therapy have been well recognized as risk factors for mortality; however the fact that early mortality was clearly superior in the HCRP group strongly suggests that host related factors are crucial in terms of mortality in BPP. P> References
(1) Venditti M, Falcone M, Corrao S, Licata G, Serra P; Study Group of the Italian Society of Internal Medicine. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital -acquired pneumonia. Ann Intern Med. 2009; 150:19-26.
(2) Micek ST, Kollef KE, Reichley RM, Roubinian N, Kollef MH. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother. 2007; 51:3568-73.
(3) Kollef MH, Shorr A, Tabak YP, Gupta V, Liu LZ, Johannes RS. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest. 2005; 128:3854-62.
(4) Carratalà J, Mykietiuk A, Fernández-Sabé N, Suárez C, Dorca J, Verdaguer R,Manresa F, Gudiol F. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. Arch Intern Med. 2007; 167:1393-9.
None declared
Pneumonia in patients
who were recently hospitalized, reside in a long-term health facility, or are
receiving hemodialysis or intravenous chemotherapy is known as health
care–associated pneumonia. Health care–associated pneumonia seems to differ
from pneumonia that occurs in patients without these characteristics. Data that validate this
proposal are scanty. In this context we read with great interest the paper by
Venditti et al entitled “Outcomes of Patients Hospitalized With
Community-Acquired (CAP), Health Care–Associated (HCAP), and Hospital-Acquired
Pneumonia (HAP)” (1). We would like to contribute to this topic presenting data
obtained on a large group of elderly patients admitted to our Department of
Internal Medicine and Geriatrics (Poliambulanza General Hospital -Brescia, Italy).
From July 2005 to
December 2007, 356 patients with pneumonia
were consecutively admitted (mean age = 81.1±8.4 years). Pneumonia was diagnosed by clinical signs and chest
radiography and treatment done according to the ATS/ATS-IDSA guidelines (2);
its severity was assessed
according to CURB-65 (Confusion or dementia, Urea nitrogen, Respiratory rate,
Blood pressure, and age 65 years or older) score (3).
Characteristics of patients
were obtained after a
multidimensional evaluation, including information on
demographics (age, sex, living site prior to admission), cognitive status,
functional status (i.e. presence of disability two weeks before the acute
event), and physical health performed after admission using a standard
protocol, by a trained staff of physicians; physical health was evaluated by the detection of
single diseases, comorbidity (computed by the Charlson index), and by the
evaluation of physiologic severity (computed by the APACHE II score). Number of currently administered drugs was also recorded (4).
We classified patients
as having Hospital-Acquired Pneumonia (n=45) if they received their diagnosis
after being hospitalized for more than 72 hours or within 10 days of leaving the
hospital. Affected by Health Care–Associated Pneumonia (n=76, of whom 33 admitted
directly from Nursing Homes) were those patients with pneumonia who have had a
recent contact with the health care system through nursing homes, hemodialysis
clinics, or hospitalization in previous 6 months. We classified patients as having Community Acquired
Pneumonia (n=235) if they did not fit the criteria for either health
care–associated or hospital-acquired pneumonia.
In hospital and three months mortality were the outcome measure of our
analysis.
Characteristics
and the survival of patients of the three pneumonia groups (i.e. CAP,
HCAP, and HAP) are
shown in table: in comparison with patients affected by CAP, severity of somatic, biological,
psychic, and functional conditions was higher in patients affected by HCAP and
in those with HAP. In
hospital and three-month mortality were 9.8 and 27.7% in patients with CAP,
18.4 and 38.2% in patients with HCRP, and 22.2 and 44.4 % in those with HAP respectively.
Our data agree with those by Venditti et al and
provide further evidence supporting that HCRP represents a distinct subset of
pneumonia. In fact, also in our study, if compared with elderly patients who
have CAP, those with HCRP have more severe disease and a mortality rate close to
that of patients with HAP.
In order to provide an optimal clinical management
this
subset of pneumonia requires not only specific antibiotic therapy but also a
multidimensional approach considering frailty, comorbidity, dementia, and
disability, all of these independently associated with poor prognosis (5).
Finally, it is important to emphasize that, due to
the progressive increase of intermediate
elderly care facilities between hospitals and home, that will take place in
the next future, the prevalence of HCRP will increase. This fact will stimulate
the attention of clinicians to maximize treatment efficacy in a broader number
of patients.
1.
Venditti M, Falcone M,
Corrao S, Licata G, Serra P, and the Study Group of the Italian Society of
Internal Medicine. Outcomes of patients
hospitalized with Community-Acquired, Health Care–Associated, and
Hospital-Acquired Pneumonia. Ann
Intern Med. 2009; 150:19-26.
2.
American Thoracic
Society, Infectious Diseases Society of America. Guidelines for the management
of adults with hospital-acquired, ventilator-associated, and
healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005; 171:388-416.
3.
Lim WS, van der Eerden MM,
Laing R, et al. Defining community
acquired pneumonia severity on presentation to hospital: an international
derivation and validation study. Thorax. 2003; 58:377-82.
4.
Rozzini R, Sabatini T, Cassinadri A et al. Relationship between
functional loss before hospital admission and mortality in elders with medical
illness J Gerontol A Biol Sci Med Sci. 2005; 60:1180-3
5.
Rozzini R, Sabatini T, Trabucchi M. Is
pneumonia still the old man's friend? Arch Intern Med. 2003; 163:1491-2.
Table. Characteristics, in hospital and
3-months mortality rate of 356 Elderly Patients Hospitalized for Community-Acquired (CAP), Health Care–Associated (HCAP), and
Hospital-Acquired Pneumonia (HAP)
|
|
|
|
|
|
|
|
|
|
CAP
|
HCAP
|
|
HAP
|
|
|
|
|
(N=235)
|
(N=76)
|
P*
|
(N=45)
|
P†
|
P‡
|
|
|
|
|
|
|
|
|
|
|
M+SD/ N (%)
|
M+SD (%)
|
|
M+SD (%)
|
|
|
|
|
|
|
|
|
|
|
|
Age (years)
|
81.6+8.2
|
81.2+8.9
|
0.785
|
78.7+8.5
|
0.033
|
0.118
|
|
Gender (males)
|
115 (48.9)
|
35 (46.1)
|
0.380
|
20 (44.4)
|
0.349
|
0.507
|
|
|
|
|
|
|
|
|
|
Urea Nitrogen (mg/dl)
|
66.6+39.6
|
75.7+52.5
|
0.122
|
79.1+54.1
|
0.077
|
0.741
|
|
Creatinine (mg/dl)
|
1.3+0.8
|
1.5+1.0
|
0.095
|
1.2+0.8
|
0.638
|
0.148
|
|
CPR (mg/dl)
|
9.4+10.4
|
10.3+10.2
|
0.506
|
11.7+10.1
|
0.181
|
0.478
|
|
Serum Albumin (g/dl)
|
3.4+0.6
|
3.1+0.6
|
0.009
|
2.9+0.6
|
0.000
|
0.101
|
|
Hemoglobin (g/dl)
|
12.3+2.2
|
11.8+2.4
|
0.086
|
11.2+2.1
|
0.003
|
0.191
|
|
|
|
|
|
|
|
|
|
Delirium
|
46 (19.6)
|
17 (22.4)
|
0.353
|
18 (40.0)
|
0.004
|
0.032
|
|
Dementia
|
85 (38.6)
|
37 (51.4)
|
0.039
|
24 (58.5)
|
0.014
|
0.100
|
|
Chronic Obstructive Pulmonary Diseases
|
117 (49.8)
|
38 (50.0)
|
0.540
|
26 (57.8)
|
0.206
|
0.261
|
|
Heart failure (NYHA III-IV)
|
82 (34.9)
|
35 (46.1)
|
0.055
|
15 (33.3)
|
0.493
|
0.118
|
|
Renal Failure
|
56 (24.0)
|
26 (35.6)
|
0.038
|
12 (27.9)
|
0.356
|
0.259
|
|
Malnutrition
|
41 (17.8)
|
23 (30.7)
|
0.015
|
19 (39.5)
|
0.002
|
0.218
|
|
Stroke
|
30 (12.8)
|
15 (19.7)
|
0.097
|
11 (24.4)
|
0.041
|
0.349
|
|
Cancer
|
27 (11.5)
|
12 (15.8)
|
0.217
|
8 (17.8)
|
0.179
|
0.482
|
|
|
|
|
|
|
|
|
|
Diseases (n)
|
3.9+1.9
|
4.2+1.6
|
0.248
|
4.3+1.8
|
0.136
|
0.569
|
|
Charlson Index
|
2.9+1.9
|
3.2+1.8
|
0.191
|
4.1+2.9
|
0.000
|
0.040
|
|
Drugs (n)
|
6.5+3.2
|
7.1+3.5
|
0.244
|
8.0+3.6
|
0.009
|
0.205
|
|
|
|
|
|
|
|
|
|
Disabled (2 wks before admission)
|
42 (17.9)
|
25 (32.9)
|
0.006
|
15 (33.3)
|
0.019
|
0.557
|
|
|
|
|
|
|
|
|
|
APACHE II score§
|
14.9+5.4
|
17.3+7.0
|
0.002
|
17.7+6.4
|
0.007
|
0.789
|
|
APACHE II-APS subscore||
|
7.3.9+6.2
|
9.8+6.9
|
0.003
|
10.9+5.9
|
0.003
|
0.874
|
|
CURB-65 High risk score (Class III)**
|
118 (50.2)
|
42 (55.3)
|
0.263
|
28 (62.2)
|
0.094
|
0.289
|
|
|
|
|
|
|
|
|
|
Length of stay (days)
|
6.7+3.4
|
6.5+3.8
|
0.811
|
8.2+5.3
|
0.013
|
0.050
|
|
In hospital mortality
|
23 (9.8)
|
14 (18.4)
|
0.038
|
10 (22.2)
|
0.022
|
0.389
|
|
Total 3 months mortality
|
65 (27.7)
|
29 (38.2)
|
0.011
|
20 (44.4)
|
0.021
|
0.312
|
|
|
|
|
|
|
|
|
§ APACHE II= Acute Physiology and Chronic Health Evaluation II
|| APACHE II-APS= APACHE II-Acute Physiologic Subscore
** CURB-65= Confusion or dementia, Urea nitrogen, Respiratory
rate, Blood pressure, and age 65 years or older.
Significant differences between groups were valued
using the independent t test and the chi test for continuous and dichotomyc
variables respectively:
* for comparison between
health care–associated and community-acquired pneumonia.
† for comparison between hospital-acquired and
community-acquired pneumonia.
‡ for comparison between hospital-acquired and health
care–associated pneumonia.
None declared